Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, demonstrating that participants treated with Kisunla (donanemab-azbt) for early symptomatic Alzheimer’s disease showed a continued slowing of decline over three years.
AstraZeneca‘s supplemental biologics license application (sBLA) for Imfinzi (durvalumab) has been approved and given priority review in the U.S. FDAÂ for the treatment of patients with [Read More…]
One of the most intriguing and intricate organelles in eukaryotic cells is the endoplasmic reticulum (ER), which is essential for calcium homeostasis, lipid metabolism, and [Read More…]
Novo Nordisk reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a favorable opinion, suggesting that [Read More…]
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under accelerated review, recommending lenacapavir, the company’s [Read More…]
AstraZeneca announced that its novel nanobody, gefurulimab, has successfully met its primary and all secondary endpoints in the PREVAIL Phase III trial for adults with generalized myasthenia gravis (gMG). The results showed that the once-weekly, self-administered treatment delivered statistically significant and clinically meaningful improvements in daily living activities for patients with this rare autoimmune disease.
The European Commission (EC) has granted a landmark approval for Johnson & Johnson’s DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma (SMM). This decision marks a significant shift in the treatment paradigm for this precursor to active multiple myeloma, moving away from the traditional “watch and wait” approach to proactive, early therapeutic intervention.
A groundbreaking real-world study has revealed that Beyfortus (nirsevimab-alip) significantly reduces the incidence of respiratory syncytial virus (RSV) disease in infants. The largest of its kind in the United States, the study demonstrated an 87% reduction in RSV cases requiring a visit to a doctor or hospital and a 98% decrease in hospitalizations among infants who received the treatment.
AstraZeneca has announced a landmark $50 billion investment in the United States through 2030, a strategic initiative designed to significantly enhance America’s leadership in pharmaceutical innovation.
AstraZeneca announced groundbreaking results from its FLAURA2 Phase III trial, revealing that Tagrisso (osimertinib) combined with chemotherapy offers a statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
